NL-OMON36931CompletedPhase 4
SubCutaneous Immunotherapy Treatment Effect (CITE) study - CITE study
Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites80 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •18 years or older
- •Clinically relevant moderate to severe allergic rhinitis due to a sensitization for one or two allergens: birch pollen (BP), and/or house dust mite (HM).
- •Positive nasal challenge test to the relevant allergen (BP and/or HM)
Exclusion Criteria
- •Severe/instable asthma
- •Previous immunotherapy
- •General contraindications to immunotherapy (according to international guidelines; i.e. history of anaphylaxis; immunosuppressive treatment etc).
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Efficacy of the epicutaneous immunotherapy for food allergy -Selection of skin sticking device and allergenmilk allergyJPRN-UMIN000037562Tokai University Hachioji Hospital40
Recruiting
Phase 2
Epicutaneous Immunotherapy for Egg AllergyEgg allergyEgg allergy, epicutaneous immunotherapyJPRN-jRCTs031200307Iwai Fumiko63
Completed
Phase 2
Efficacy and safety of epicutaneous immunotherapy for severe egg allergyFood allergyJPRN-UMIN000022348ational Hospital Organization Mie National Hospital40
Completed
Phase 2
Efficacy and safety of epicutaneous immunotherapy for severe milk allergyFood allergyJPRN-UMIN000024564ational Hospital Organization Mie National Hospital46
Completed
Phase 2
Efficacy and safety of epicutaneous immunotherapy for severe egg allergy; Long term trialFood allergyJPRN-UMIN000025381ational Hospital Organization Mie National Hospital20